Column Capital Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Column Capital Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$6.37K	Hold	412	–	–	﹤0.01%	575
2023 Q2	$6.47K	Hold	412	–	–	﹤0.01%	591
2023 Q1	$6.79K	Buy	412 +305	+285%	+$4.86K	﹤0.01%	607
2022 Q4	$1.67K	Hold	107	–	–	﹤0.01%	716
2022 Q3	$1K	Hold	107	–	–	﹤0.01%	704
2022 Q2	$2K	Sell	107 -314	-75%	-$4.48K	﹤0.01%	649
2022 Q1	$6K	Buy	421 +345	+454%	+$5.07K	﹤0.01%	564
2021 Q4	$1K	Sell	76 -322	-81%	-$4.52K	﹤0.01%	759
2021 Q3	$7K	Hold	398	–	–	﹤0.01%	514
2021 Q2	$7K	Hold	398	–	–	﹤0.01%	516
2021 Q1	$7K	Hold	398	–	–	﹤0.01%	509
2020 Q4	$7K	Hold	398	–	–	﹤0.01%	504
2020 Q3	$7K	Hold	398	–	–	﹤0.01%	499
2020 Q2	$7K	Hold	398	–	–	﹤0.01%	534
2020 Q1	$6K	Hold	398	–	–	﹤0.01%	479
2019 Q4	$7K	Buy	+398	New	+$7.61K	﹤0.01%	500

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Column Capital Advisors's TAK Position: Q3 2023 in Review

Column Capital Advisors held its Takeda Pharmaceutical (TAK) position steady in Q3 2023 at 412 shares worth $6.37K. The position accounts for ﹤0.01% of the portfolio, ranked #575.

Column Capital Advisors first reported a position in TAK in Q4 2019 and has held it in 16 quarters since. The position peaked at $7K in Q3 2021. 313 funds tracked by Wall St. Rank hold TAK as of Q3 2023.

Column Capital Advisors held 412 shares of Takeda Pharmaceutical worth $6.37K as of Q3 2023.
Column Capital Advisors left its Takeda Pharmaceutical share count unchanged in Q3 2023.
Takeda Pharmaceutical made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #575 holding.
Column Capital Advisors first reported a position in Takeda Pharmaceutical in Q4 2019 and has held it in 16 quarters since.
Column Capital Advisors's Takeda Pharmaceutical position peaked at $7K in Q3 2021.
313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.